• Citer

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents

par Neri, Emanuele;Manfredi, Riccardo;Marti-Bonmati, Luis;Matos Pinto De Almeida, Celso ;Merkle, Elmar Max;De Op Beeck, Bart;Schima, Wolfgang;Skehan, Stephen;Vilgrain, Valérie;Zech, Christoph Johannes C.;Bartolozzi, Carlo;Bali, Maria Antonietta ;Ba-Ssalamah, Ahmed;Boraschi, Piero;Brancatelli, Giuseppe;Caseiro-Alves, Filipe;Grazioli, Luigi;Helmberger, Thomas K G T.;Lee, Jeongmin J.M.
Référence European radiology, 26, 4, page (921-931)
Publication Publié, 2016-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Objectives: To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents. Methods: The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus. Results: Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases. Conclusions: The consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases. Key points: • Liver-specific contrast agents are recommended in MRI of the liver. • The hepatobiliary phase improves the detection and characterization of hepatocellular lesions. • Liver-specific contrast agents can improve the detection of HCC.